Huan Deng, Gregoriy A Dokshin, Jing Lei, Adam M Goldsmith, Khalil N Bitar, Diane C Fingar, Marc B Hershenson, J Kelley Bentley
Index: J. Biol. Chem. , 10198-207, (2008)
Full Text: HTML
We examined the role of glycogen synthase kinase-3beta (GSK-3beta) inhibition in airway smooth muscle hypertrophy, a structural change found in patients with severe asthma. LiCl, SB216763, and specific small interfering RNA (siRNA) against GSK-3beta, each of which inhibit GSK-3beta activity or expression, increased human bronchial smooth muscle cell size, protein synthesis, and expression of the contractile proteins alpha-smooth muscle actin, myosin light chain kinase, smooth muscle myosin heavy chain, and SM22. Similar results were obtained following treatment of cells with cardiotrophin (CT)-1, a member of the interleukin-6 superfamily, and transforming growth factor (TGF)-beta, a proasthmatic cytokine. GSK-3beta inhibition increased mRNA expression of alpha-actin and transactivation of nuclear factors of activated T cells and serum response factor. siRNA against eukaryotic translation initiation factor 2Bepsilon (eIF2Bepsilon) attenuated LiCl- and SB216763-induced protein synthesis and expression of alpha-actin and SM22, indicating that eIF2B is required for GSK-3beta-mediated airway smooth muscle hypertrophy. eIF2Bepsilon siRNA also blocked CT-1- but not TGF-beta-induced protein synthesis. Infection of human bronchial smooth muscle cells with pMSCV GSK-3beta-A9, a retroviral vector encoding a constitutively active, nonphosphorylatable GSK-3beta, blocked protein synthesis and alpha-actin expression induced by LiCl, SB216763, and CT-1 but not TGF-beta. Finally, lungs from ovalbumin-sensitized and -challenged mice demonstrated increased alpha-actin and CT-1 mRNA expression, and airway myocytes isolated from ovalbumin-treated mice showed increased cell size and GSK-3beta phosphorylation. These data suggest that inhibition of the GSK-3beta/eIF2Bepsilon translational control pathway contributes to airway smooth muscle hypertrophy in vitro and in vivo. On the other hand, TGF-beta-induced hypertrophy does not depend on GSK-3beta/eIF2B signaling.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
SB216763
CAS:280744-09-4 |
C19H12Cl2N2O2 |
Lenticular mitoprotection. Part B: GSK-3β and regulation of ...
2013-01-01 [Mol. Vis. 19 , 2451-67, (2013)] |
Involvement of the glycogen synthase kinase-3 signaling path...
1989-07-01 [PLoS ONE 6(9) , e24648, (2011)] |
Selective small-molecule inhibitors of glycogen synthase kin...
2001-04-01 [J. Neurochem. 77 , 94-102 , (2001)] |
Lithium upregulates vascular endothelial growth factor in br...
2009-02-01 [Stroke 40(2) , 652-5, (2009)] |
Delayed cardioprotection afforded by the glycogen synthase k...
2008-03-01 [Am. J. Physiol. Heart Circ. Physiol. 294(3) , H1497-500, (2008)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved